Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
AssigneeErrant Gene Therapeutics, LLC
InventorsHsuan-Lin Lan-Hargest, Robert J. Kaufman
Life of this patent
Estimating the term…
Loading patent…
AssigneeErrant Gene Therapeutics, LLC
InventorsHsuan-Lin Lan-Hargest, Robert J. Kaufman
Estimating the term…
Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-ketoepoxide group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or to stimulate hematopoietic cells ex vivo.
A method of inhibiting histone deacetylation activity in cells comprising contacting the cells with an effective amount of a compound containing an alpha-ketoepoxide group, wherein the compound is not trapoxin, thereby treating one or more disorders mediated by histone deacetylase or stimulating hematopoietic cells ex vivo, and
Dependencies are inferred from the claim text.